In short
TROFOLASTAT clinical trials are studying imaging use in people with prostate cancer. The main goal is to compare how well the study scans find disease, especially local lymph node spread, and to see which approach gives better staging information. The trial data focus on adults with prostate cancer in a Phase 4 study.
Key points
- TROFOLASTAT is being studied in a Phase 4 trial for prostate cancer staging. The trial compares an experimental imaging approach with a control scan to see which one better finds local lymph node metastases. The study plans to enroll 320 people. Its main goal is to measure how many patients have lymph node spread detected by each scan method. The trial is authorised and uses an interventional design.
Trial overview
The available trial data show one authorised study of TROFOLASTAT in people with prostate cancer. This study is called PROSTAMIP and is a comparative, prospective, randomized trial for primary prostate cancer staging.
The study is looking at whether the experimental imaging arm can detect local lymph node metastases better than the control arm. In simple terms, the researchers want to know which scan is better at finding cancer spread to nearby lymph nodes.
Who is being studied
The trial targets people with prostate cancer who need imaging for staging. Staging means checking how far the cancer has spread in the body.
The planned enrollment is 320 participants. This size allows the researchers to compare the imaging groups in a larger patient group.
What is being compared
The study compares three imaging-related options listed in the trial data: 18F-PSMA-1007, Pylclari, and 99mTc-MIP-1404. The brief summary says the experimental arm uses 99mTc-MIP-1404 SPECT/CT, while the control arm uses ce-wbCT.
SPECT/CT is an imaging test that combines two scan methods to help show where disease may be found. The trial is testing whether the experimental scan gives better staging information than the control scan.
Study phase and design
This is a Phase 4 study. Phase 4 studies are later-stage trials, often used to compare how a test performs in clinical practice.
The study type is interventional, which means the researchers assign participants to study groups rather than only observing them. The title also says the trial is prospective and randomized, meaning people are followed forward in time and placed into groups by chance.
Main outcome being measured
The primary outcome is the proportion of subjects with local lymph node metastases in the control and experimental arms, as read by the study readers. A primary outcome is the main result the trial is designed to measure.
This outcome is important because it shows how often each imaging method finds nearby lymph node spread. The brief summary states that the experimental arm is expected to be superior in detecting these metastases compared with the control arm.
What the results may mean
If the experimental imaging approach finds more local lymph node metastases, it may help doctors stage prostate cancer more accurately. Better staging can support more informed treatment planning because it gives a clearer picture of disease spread.
At this stage, the trial data only describe the study aim and design, not final results. So the main focus is on comparing imaging performance in prostate cancer, not on treatment outcomes.